Episode 57: The KOMET-007 Trial episode artwork

EPISODE · Jul 9, 2026 · 19 MIN

Episode 57: The KOMET-007 Trial

from Healthcare Unfiltered Express · host Chadi Nabhan

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements. A must listen - please share subscribe, and join the conversation.

Episode metadata supplied by the publisher feed · Published Jul 9, 2026

Embed this episode

NOW PLAYING

Episode 57: The KOMET-007 Trial

0:00 19:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Healthcare Unfiltered Express?

This episode is 19 minutes long.

When was this Healthcare Unfiltered Express episode published?

This episode was published on July 9, 2026.

Can I download this Healthcare Unfiltered Express episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!